About Hypera
Hypera is a publicly listed company. Prescription and over-the-counter pharmaceuticals are manufactured, including generics and supplements. Its website hypera.com.br draws about 296 thousand monthly visits. Hypera offers products and services including Over-the-counter Products and Prescription Drugs. Its focus areas include Traditional Nutraceuticals and Diversified. Its legal entity is Hypera Pharma S.A.
Company details
Pharmaceuticals encompassing prescription and over-the-counter categories are produced, with a focus on generic medications, dermocosmetics, and nutritional supplements. Operations span multiple segments of the pharmaceutical sector, where a diversified portfolio of products is maintained. Investments are directed toward innovation and sustainable growth to support health improvements. Offerings are extended to individual consumers and institutional clients such as clinics and hospitals.
- Stage Public
- SectorsHealthcare
- Website category Finance · Investing
- Website hypera.com.br
- Social LinkedIn Instagram
- Legal Name Hypera S.A.
- Annual Revenue$1.41 B (USD)3.45as on Dec 31, 2025
- Net Profit$219.07 M (USD)-10.86as on Dec 31, 2025
- EBITDA$374.24 M (USD)3.05as on Dec 31, 2025
Products & Services of Hypera
Hypera offers a comprehensive portfolio of products and services, including Over-the-counter Products and Prescription Drugs.
These products are provided for everyday health needs and are led by iconic brands in the market.
Prescription drugs are supplied through established brands like Mantecorp Farmasa to meet clinical requirements.
People of Hypera
161 people are tracked at Hypera (20 in leadership, 9 in board & advisors, 132 in team).
| Name | Role | Group |
|---|---|---|
Breno Oliveira | CEO | Leadership |
Ramon Sanches Frutuoso Silva | CFO | Leadership |
Tobias Henzel | Head Business Unit Non-retail Market | Leadership |
Aluany Luz | Consultor | HR Business Partner | Leadership |
Lincoln Alves da Costa | IT Executive - Head Of IT Project Execution | Leadership |
Carla Ramalho | Senior HR Business Partner | Leadership |
Celio Jose Silva Santos | Coordenador De Planejamento Financeiro (fp&a) | Skincare (business Partner) | Leadership |
Beatriz Gomes Lima | Sales, Franchise And Operations Head At Bioage Skincare | Leadership |
Lucas Silva | Consultor De Negócios - IT Business Partner | Leadership |
Douglas Vieira | Sr IT Business Partner | Leadership |
Aline Guarnieri Paz | Consultora De Gente & Gestão - HR Business Partner | Leadership |
Rafaella Carvalhaes Viana Lino | HRBP Sênior | Human Resoucers Business Partner | Leadership |
Vitalii Shevchenko | Head Of Recruiting | Leadership |
José Neto | Director Of Quality Control | Leadership |
Tadeu Tavares | Head Of Operations Infrastructure & Security | Leadership |
Flavio Pioltini | Strategic Planning & Projects Director | Leadership |
Willian Braidott | Supply Chain Director | Leadership |
Rafael Batista | Diretor Executivo De Operações - COO | Leadership |
Carla Dias Araújo | CMO / Branding, Communication And Digital Head | Leadership |
Mauricio Christovam | People&management Executive Director | Leadership |
141 more people are available in the full profile.
Complete people profiles for Hypera
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Hypera
Hypera is a publicly listed company on the BMFBOVESPA with ticker symbol HYPE3 in Brazil, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date18 Apr 2008
- Listed onB3: HYPE3
- Listed entityHypera S.A.
- Exchange sectorHealth technology
- ISINBRHYPEACNOR0
- Share price26.00 BRL (-3.45% on the day) · 2026-10-13
- Market capitalisation18,290,369,995.00 BRL
- Price to earnings9.8
- EPS (diluted, trailing year)2.65 BRL
- Dividend yield4.15%
- Volume (last session)6,115,800
Financials of Hypera
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 7.70B BRL | 1.20B BRL | 2.05B BRL |
| 2024 | 7.44B BRL | 1.34B BRL | 1.99B BRL |
| 2023 | 7.91B BRL | 1.65B BRL | 2.70B BRL |
| 2022 | 7.55B BRL | 1.70B BRL | 2.65B BRL |
| 2021 | 5.94B BRL | 1.33B BRL | 2.03B BRL |
Detailed financial statements for Hypera
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of Hypera
The website of Hypera (hypera.com.br) receives about 296.1K visits a month and ranks #148,737 among all websites worldwide, #9,245 in Investing.
- Monthly visits296.1K
▼ 33.7% vs previous month
- Unique visitors237.1K
per month
- Global rank#148,737
among all websites
- Category rank#9,245
Finance · Investing
- Bounce rate26%
- Pages per visit1.3
- Average visit41 sec
- DevicesDesktop 6% · Mobile 94%
Websites whose visitors overlap most with Hypera. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| seudinheiro.com | 100% | #61,024 | View details | ||
braziljournal.com | braziljournal.com | 67% | #81,961 | – | |
ihypera.com.br | ihypera.com.br | 62% | #531,618 | – | |
infomoney.com.br | infomoney.com.br | 56% | #3,114 | – | |
mercadolivre.com.br | mercadolivre.com.br | 33% | #90 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hypera
Complete news archive for Hypera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hypera
Annual revenue of Hypera is $1.41B as on Dec 31, 2025.
Pharmaceuticals encompassing prescription and over-the-counter categories are produced, with a focus on generic medications, dermocosmetics, and nutritional supplements. Operations span multiple segments of the pharmaceutical sector, where a diversified portfolio of products is maintained. Investments are directed toward innovation and sustainable growth to support health improvements. Offerings are extended to individual consumers and institutional clients such as clinics and hospitals.
Hypera offers Over-the-counter Products and Prescription Drugs.
Yes, Hypera is publicly traded on BMFBOVESPA under the ticker symbol HYPE3.
Hypera operates through Hypera Pharma S.A..
The website of Hypera receives about 296 thousand visits a month and ranks #148,737 among all websites worldwide.